Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Alyson Clayborn"'
Autor:
Zhan Xu, David E. Rauch, Rania M. Mohamed, Sanaz Pashapoor, Zijian Zhou, Bikash Panthi, Jong Bum Son, Ken-Pin Hwang, Benjamin C. Musall, Beatriz E. Adrada, Rosalind P. Candelaria, Jessica W. T. Leung, Huong T. C. Le-Petross, Deanna L. Lane, Frances Perez, Jason White, Alyson Clayborn, Brandy Reed, Huiqin Chen, Jia Sun, Peng Wei, Alastair Thompson, Anil Korkut, Lei Huo, Kelly K. Hunt, Jennifer K. Litton, Vicente Valero, Debu Tripathy, Wei Yang, Clinton Yam, Jingfei Ma
Publikováno v:
Cancers, Vol 15, Iss 19, p 4829 (2023)
Accurate tumor segmentation is required for quantitative image analyses, which are increasingly used for evaluation of tumors. We developed a fully automated and high-performance segmentation model of triple-negative breast cancer using a self-config
Externí odkaz:
https://doaj.org/article/13a3720095084e2faf7f2ac9d1c1eb92
Autor:
Clinton Yam, Elizabeth A. Mittendorf, Haven R. Garber, Ryan Sun, Senthil Damodaran, Rashmi K. Murthy, David Ramirez, Meghan Karuturi, Rachel M. Layman, Nuhad Ibrahim, Gaiane M. Rauch, Beatriz E. Adrada, Rosalind P. Candelaria, Jason B. White, Elizabeth Ravenberg, Alyson Clayborn, Qing Qing Ding, W. Fraser Symmans, Sabitha Prabhakaran, Alastair M. Thompson, Vicente Valero, Debu Tripathy, Lei Huo, Stacy L. Moulder, Jennifer K. Litton
Publikováno v:
Breast Cancer Research and Treatment. 199:457-469
Autor:
Tapsi Kumar, Yiyun Lin, Yun Yan, Shanshan Bai, Jianzhuo Li, Tuan Tran, Min Hu, Elizabeth Ravenberg, Maia Rauch, Alyson Clayborn, Alastair Thompson, Lei Huo, Stacy Moulder, Clinton Yam, Nicholas Navin
Publikováno v:
Cancer Research. 83:2147-2147
Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer that lacks the expression of estrogen receptor (ER), progesterone receptor (PR) and HER2 and therefore have limited hormonal treatment options. Neoadjuvant chemotherapy (N
Autor:
Rania M. Mohamed, Bikash Panthi, Beatriz Adrada, Rosalind Candelaria, Mary S. Guirguis, Wei Yang, Medine Boge, Miral Patel, Nabil Elshafeey, Sanaz Pashapoor, Zijian Zhou, Jong Bum Son, Ken-Pin Hwang, H. T. Carisa Le-Petross, Jessica Leung, Marion E. Scoggins, Gary J. Whitman, Zhan Xu, Deanna L. Lane, Tanya Moseley, Frances Perez, Jason White, Elizabeth Ravenberg, Alyson Clayborn, Mark Pagel, Huiqin Chen, Jia Sun, Peng Wei, Alastair M. Thompson, Stacy Moulder, Anil Korkut, Lei Huo, Kelly K. Hunt, Jennifer K. Litton, Vicente Valero, Debu Tripathy, Clinton Yam, Jingfei Ma, Gaiane Rauch
Publikováno v:
Cancer Research. 83:P6-01
PURPOSE Triple negative breast cancer (TNBC) is an aggressive and heterogeneous subtype of breast cancer. Pathologic complete response (pCR) to neoadjuvant systemic therapy (NAST) predicts better survival. Early prediction of the treatment response c
Autor:
Clinton Yam, Ziyi Li, Anil Korkut, Wencai Ma, Elisabeth Kong, Holly A. Hill, Hussein Abbas, Sausan Abouharb, Beatriz Adrada, Banu K. Arun, Carlos H. Barcenas, Ajit Bisen, Daniel Booser, Aman Buzdar, Rosalind Candelaria, Junjie Chen, Alyson Clayborn, Senthil Damodaran, Qingqing Ding, Haven Garber, Gabriel N. Hortobagyi, Kelly K. Hunt, Nuhad K. Ibrahim, Adaeze Iheme, Meghan S. Karuturi, Kimberly Koenig, Rachel M. Layman, Jangsoon Lee, Jennifer K. Litton, Melissa Mitchell, Giancarlo Moscol, Jason Mouabbi, Rashmi K. Murthy, Oluchi Oke, Paula Pohlmann, David Ramirez, Elizabeth Ravenberg, Sadia Saleem, Mediget Teshome, Vicente Valero, Jason White, Madison Williams, Wendy Woodward, Chasity Yajima, Naoto T. Ueno, Ken Chen, Gaiane Rauch, Lei Huo, Debu Tripathy
Publikováno v:
Cancer Research. 83:HER2-01
Background: In the metastatic setting, low HER2 expression is associated with clinical benefit from trastuzumab deruxtecan, a HER2-targeting antibody drug conjugates. However, little is known about the biological significance of low HER2 expression i
Autor:
Bikash Panthi, Rania M. Mohamed, Beatriz Adrada, Rosalind Candelaria, Mary S. Guirguis, Wei Yang, Medine Boge, Miral Patel, Nabil Elshafeey, Sanaz Pashapoor, Zijian Zhou, Jong Bum Son, Ken-Pin Hwang, H. T. Carisa Le-Petross, Jessica Leung, Marion E. Scoggins, Gary J. Whitman, Zhan Xu, Deanna L. Lane, Tanya Moseley, Frances Perez, Jason White, Elizabeth Ravenberg, Alyson Clayborn, Mark Pagel, Huiqin Chen, Jia Sun, Peng Wei, Alastair M. Thompson, Stacy Moulder, Anil Korkut, Lei Huo, Kelly K. Hunt, Jennifer K. Litton, Vicente Valero, Debu Tripathy, Clinton Yam, Jingfei Ma, Gaiane Rauch
Publikováno v:
Cancer Research. 83:P6-01
Background and Purpose Early prediction of neoadjuvant systemic therapy (NAST) response in triple negative breast cancer (TNBC) patients could potentially aid in the selection of alternative therapies and avoid unnecessary toxicity in patients unlike
Autor:
Lei Huo, Gaiane M. Rauch, Alyson Clayborn, Tanbin Rahman, Pamela McCarthy, David Ramirez, Elizabeth Ravenberg, Sadia Saleem, Stacy L. Moulder, Clinton Yam, W. Fraser Symmans, Jason B White, James Stec, Sausan Abouharb, Bora Lim, Jennifer K. Litton, Senthil Damodaran, Meghan Sri Karuturi, Ryan Sun
Publikováno v:
Investigational New Drugs. 39:509-515
Folate receptor alpha (FRα) has been reported to be expressed in up to 80% of triple-negative breast cancers (TNBC) with limited expression in normal tissues, making it a promising therapeutic target. Mirvetuximab soravtansine (mirvetuximab-s) is an
Autor:
Debu Tripathy, Clinton Yam, Alastair M. Thompson, Senthil Damodaran, Beatriz E. Adrada, Lei Huo, Elizabeth A. Mittendorf, Rashmi Krishna Murthy, Sabitha Prabhakaran, William Fraser Symmans, Stacy L. Moulder, Sahil Seth, Jason B White, Ryan Sun, Rosalind P. Candelaria, Vicente Valero, Elizabeth Ravenberg, Gaiane M. Rauch, Alyson Clayborn, Jennifer K. Litton
Publikováno v:
Journal of Clinical Oncology. 39:592-592
592 Background: Neoadjuvant anti-PD-(L)1 therapy confers an improvement in pathological complete response (pCR) rate in unselected TNBC. However, given the potential for long-term morbidity from immune related adverse events (irAE), it is important t
Autor:
Kenneth R. Hess, Elizabeth Ravenberg, Alyson Clayborn, Stacy L. Moulder, Salyna Meas, Anthony Lucci, Carolyn S. Hall, Alastair M. Thompson
Publikováno v:
Journal of Clinical Oncology. 37:e12111-e12111
e12111 Background: ARTEMIS (A Randomized, TNBC Enrolling trial to confirm Molecular profiling Improves Survival) is a randomized trial to determine if precision guided neoadjuvant chemotherapy (NAC) influences rates of pathologic complete response in
Autor:
Gaiane M. Rauch, KR Hess, Chris Hall, Rosalind P. Candelaria, Alastair M. Thompson, Elizabeth Ravenberg, S. L. Moulder, Elizabeth A. Mittendorf, Alyson Clayborn, Anthony Lucci
Publikováno v:
Cancer Research. 79:P3-01
Background: ARTEMIS (A Randomized, TNBC Enrolling trial to confirm Molecular profiling Improves Survival) is a randomized trial to determine if precision guided neoadjuvant chemotherapy (NAC) impacts rates of pathologic complete response in the breas